09/09/2026
Moonwalk Biosciences, a South San Francisco, CA-based provider of adipose-targeted RNA interference (RNAi) medicines for obesity and cardiometabolic diseases, raised $70M in funding. The company intends to use the funds to support advancement of its lead obesity candidate, MW101, into first-in-human clinical studies in late 2027, expand its pipeline of tissue-targeted siRNA medicines, and further advance its proprietary discovery platform.